Christal N. Davis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christal N. Davis has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Henry R. Kranzler
Department of Psychiatry University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
26 shared publications - Joel Gelernter
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
15 shared publications - Rachel L. Kember
University of Pennsylvania
15 shared publications - Sylvanus Toikumo
University of Pennsylvania
10 shared publications - Yousef Khan
Department of Psychiatry, University of Pennsylvania School of Medicine
8 shared publications Nicholas G. Martin
QIMR Berghofer Medical Research Institute
7 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in Nature Neuroscience
Gene discovery and pleiotropic architecture of multidimensional pain in a genome-wide association study of >1.2 million individuals
Chronic pain is highly prevalent worldwide, yet its genetic architecture remains to be fully elucidated. Here we leveraged data from 1,235,695 European-ancestry individuals across three biobanks. In a meta-analytic genome-wide association study of multidimensional pain (MP), we identified 343 independent loci, 92 of which were new pain associations. Sex-specific meta-analyses revealed 115 independent loci (12 of which were new) among males ( n = 583,066) and 12 loci (2 of which were new) among females ( n = 241,266). Multi-omic gene prioritization analyses highlighted 490 genes associated with MP through their effects on brain-specific and blood-specific regulation. Mendelian randomization analyses showed causal associations between MP and psychiatric disorders, substance use disorders and C-reactive protein levels. MP variants also showed pleiotropic associations with several brain imaging-derived phenotypes. This study expands our knowledge of the genetics of pain and its pathogenesis, highlighting the importance of its pleiotropy with multiple disorders and elucidating its multi-omic pathophysiology.
- 12 November 2026
- Published by Springer Nature in Nature Neuroscience
Open AccessGene discovery and pleiotropic architecture of multidimensional pain in a genome-wide association study of >1.2 million individuals
Chronic pain is highly prevalent worldwide, yet its genetic architecture remains to be fully elucidated. Here we leveraged data from 1,235,695 European-ancestry individuals across three biobanks. In a meta-analytic genome-wide association study of multidimensional pain (MP), we identified 343 independent loci, 92 of which were new pain associations. Sex-specific meta-analyses revealed 115 independent loci (12 of which were new) among males ( n = 583,066) and 12 loci (2 of which were new) among females ( n = 241,266). Multi-omic gene prioritization analyses highlighted 490 genes associated with MP through their effects on brain-specific and blood-specific regulation. Mendelian randomization analyses showed causal associations between MP and psychiatric disorders, substance use disorders and C-reactive protein levels. MP variants also showed pleiotropic associations with several brain imaging-derived phenotypes. This study expands our knowledge of the genetics of pain and its pathogenesis, highlighting the importance of its pleiotropy with multiple disorders and elucidating its multi-omic pathophysiology.
- Open Access
Longitudinal Pain Profiles and Their Clinical and Genetic Correlates in 624,996 U.S. Veterans
Importance: Pain varies in its intensity and course, yet much of our understanding of pain is based on cross-sectional assessments or longitudinal studies of selected clinical populations. Routinely collected electronic health record data may enable characterization of longitudinal pain patterns at scale. Objective: To identify longitudinal pain profiles among U.S. Veterans and characterize their clinical and polygenic correlates. Design: Cohort study using electronic health record and genomic data from the Million Veteran Program, with up to 16 years of pain assessments collected between 2000 to 2025. Setting: U.S. Department of Veterans Affairs health care system. Participants: Million Veteran Program participants assigned to African-like, Admixed American-like, East Asian-like, European-like, or South Asian-like genetically inferred ancestry groups who have at least three years of outpatient numeric rating scale pain records. Exposures: Outpatient pain ratings and polygenic scores for psychiatric, sleep, and substance use traits. Main Outcomes and Measures: Pain profiles were identified using Gaussian finite mixture modeling of pain intensity, directional change, and within-person variability. Profiles were characterized by pain, psychiatric and substance use diagnoses, opioid exposure, body mass index, and polygenic scores. Results: Among 624,996 participants (Mean [SD] age at first pain rating=53.4 [13.5] years; 568,833 [91.0%] male), 51,731,567 outpatient pain ratings were analyzed. Three profiles were identified: stable no pain, stable mild pain, and mild-to-moderate increasing pain. Compared with the stable no pain profile, the increasing pain profile had higher odds of chronic pain (OR=21.14 [95% CI: 18.96-23.57]), opioid use disorder (OR=9.32 [95% CI: 8.31-10.45]), opioid exposure (OR=8.61 [95% CI: 8.41-8.83]), major depressive disorder (OR=3.77 [95% CI: 3.67-3.87]), and posttraumatic stress disorder (OR=3.72 [95% CI: 3.61-3.84]). Associations were attenuated but remained after adjustment for mean pain severity. Polygenic scores for depression, insomnia, attention-deficit/hyperactivity disorder, and tobacco use disorder were the most consistent predictors of increasing pain across the three largest genetically inferred ancestry groups. Conclusions and Relevance: Longitudinal modeling of routinely collected pain scores identified pain profiles associated with clinical burden and polygenic liability. These profiles captured clinically meaningful information beyond mean pain severity alone, highlighting the value of longitudinal pain phenotyping in electronic health record data. Key Points: Question: Can pain scores collected in outpatient care identify clinically meaningful pain profiles among U.S. Veterans? Findings: In this cohort study of 624,996 Veterans with more than 51 million pain ratings across up to 16 years, three pain profiles were identified: stable no pain, stable mild pain, and mild-tomoderate increasing pain. Profiles differed in clinical burden even after accounting for mean pain severity and were associated with polygenic liability for psychiatric, sleep, and substance use traits. Meaning: Routinely collected pain scores can be used to characterize heterogeneity in the course of pain and factors associated with more burdensome pain patterns.
Open AccessLongitudinal Pain Profiles and Their Clinical and Genetic Correlates in 624,996 U.S. Veterans
Importance: Pain varies in its intensity and course, yet much of our understanding of pain is based on cross-sectional assessments or longitudinal studies of selected clinical populations. Routinely collected electronic health record data may enable characterization of longitudinal pain patterns at scale. Objective: To identify longitudinal pain profiles among U.S. Veterans and characterize their clinical and polygenic correlates. Design: Cohort study using electronic health record and genomic data from the Million Veteran Program, with up to 16 years of pain assessments collected between 2000 to 2025. Setting: U.S. Department of Veterans Affairs health care system. Participants: Million Veteran Program participants assigned to African-like, Admixed American-like, East Asian-like, European-like, or South Asian-like genetically inferred ancestry groups who have at least three years of outpatient numeric rating scale pain records. Exposures: Outpatient pain ratings and polygenic scores for psychiatric, sleep, and substance use traits. Main Outcomes and Measures: Pain profiles were identified using Gaussian finite mixture modeling of pain intensity, directional change, and within-person variability. Profiles were characterized by pain, psychiatric and substance use diagnoses, opioid exposure, body mass index, and polygenic scores. Results: Among 624,996 participants (Mean [SD] age at first pain rating=53.4 [13.5] years; 568,833 [91.0%] male), 51,731,567 outpatient pain ratings were analyzed. Three profiles were identified: stable no pain, stable mild pain, and mild-to-moderate increasing pain. Compared with the stable no pain profile, the increasing pain profile had higher odds of chronic pain (OR=21.14 [95% CI: 18.96-23.57]), opioid use disorder (OR=9.32 [95% CI: 8.31-10.45]), opioid exposure (OR=8.61 [95% CI: 8.41-8.83]), major depressive disorder (OR=3.77 [95% CI: 3.67-3.87]), and posttraumatic stress disorder (OR=3.72 [95% CI: 3.61-3.84]). Associations were attenuated but remained after adjustment for mean pain severity. Polygenic scores for depression, insomnia, attention-deficit/hyperactivity disorder, and tobacco use disorder were the most consistent predictors of increasing pain across the three largest genetically inferred ancestry groups. Conclusions and Relevance: Longitudinal modeling of routinely collected pain scores identified pain profiles associated with clinical burden and polygenic liability. These profiles captured clinically meaningful information beyond mean pain severity alone, highlighting the value of longitudinal pain phenotyping in electronic health record data. Key Points: Question: Can pain scores collected in outpatient care identify clinically meaningful pain profiles among U.S. Veterans? Findings: In this cohort study of 624,996 Veterans with more than 51 million pain ratings across up to 16 years, three pain profiles were identified: stable no pain, stable mild pain, and mild-tomoderate increasing pain. Profiles differed in clinical burden even after accounting for mean pain severity and were associated with polygenic liability for psychiatric, sleep, and substance use traits. Meaning: Routinely collected pain scores can be used to characterize heterogeneity in the course of pain and factors associated with more burdensome pain patterns.
- Open Access
- 4 September 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1
Correction: Shared genetic architecture and neurobiological pathways of problematic alcohol use and anxiety disorders
- 4 September 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1
Open AccessCorrection: Shared genetic architecture and neurobiological pathways of problematic alcohol use and anxiety disorders
- Open Access
- 13 July 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-11
Shared genetic architecture and neurobiological pathways of problematic alcohol use and anxiety disorders
Problematic alcohol use (PAU) and anxiety disorders (ANX) frequently co-occur, implying shared genetic and neurobiological foundations. However, the directionality of potential causal relationships and the specific mechanisms underlying the overlap remain unclear. Thus, we investigated the shared genetic architecture and neurobiological pathways between PAU and ANX using a multimethod genomic approach. We analyzed summary statistics from genome-wide association studies (GWAS) of PAU and ANX using Mendelian Randomization to assess causal associations between ANX and PAU. We used MiXeR to assess the overall shared genomic architecture, Local Analysis of (co)Variant Association to estimate regional genetic correlations, and conjunctional false discovery rate (conjFDR) to identify individual overlapping loci. We used FUMA to map single-nucleotide polymorphisms (SNPs) to independent loci, conduct differential gene expression analyses across 30 general and 54 specific tissue types, and perform cell-type specificity analyses using a human brain cell atlas. Druggability of identified targets was also evaluated. Mendelian Randomization analyses indicated bidirectional causal associations between ANX and PAU. MiXeR identified moderate polygenic overlap (52.5%) and genetic correlation ( r g = 0.44) between the traits, with high effect direction concordance among shared estimated causal variants (86.4%). ConjFDR identified 97 shared lead SNPs, of which 89 had concordant and 8 discordant effects on PAU and ANX. These loci mapped to 97 genes, including DRD2 and PDE4B , genes linked to dopaminergic and cAMP signaling pathways, respectively. Concordant gene expression was enriched in brain, nerve, adrenal gland, esophagus, stomach, and colon, with enriched expression specifically in the prefrontal cortex, anterior cingulate cortex, hippocampus, hypothalamus, substantia nigra and amygdala. FUMA cell-type enrichment analysis identified associations predominantly in neurons from the cerebral cortex, hippocampus, and thalamus. We found substantial genetic and neurobiological overlap between PAU and ANX, highlighting reciprocal, causal relationships between the traits, with differentially expressed genes enriched in addiction- and anxiety-relevant brain regions. These findings support shared genetic and neurobiological mechanisms linking PAU and ANX, while acknowledging that some signals may reflect broader internalizing or psychiatric liability.
- 13 July 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-11
Open AccessShared genetic architecture and neurobiological pathways of problematic alcohol use and anxiety disorders
Problematic alcohol use (PAU) and anxiety disorders (ANX) frequently co-occur, implying shared genetic and neurobiological foundations. However, the directionality of potential causal relationships and the specific mechanisms underlying the overlap remain unclear. Thus, we investigated the shared genetic architecture and neurobiological pathways between PAU and ANX using a multimethod genomic approach. We analyzed summary statistics from genome-wide association studies (GWAS) of PAU and ANX using Mendelian Randomization to assess causal associations between ANX and PAU. We used MiXeR to assess the overall shared genomic architecture, Local Analysis of (co)Variant Association to estimate regional genetic correlations, and conjunctional false discovery rate (conjFDR) to identify individual overlapping loci. We used FUMA to map single-nucleotide polymorphisms (SNPs) to independent loci, conduct differential gene expression analyses across 30 general and 54 specific tissue types, and perform cell-type specificity analyses using a human brain cell atlas. Druggability of identified targets was also evaluated. Mendelian Randomization analyses indicated bidirectional causal associations between ANX and PAU. MiXeR identified moderate polygenic overlap (52.5%) and genetic correlation ( r g = 0.44) between the traits, with high effect direction concordance among shared estimated causal variants (86.4%). ConjFDR identified 97 shared lead SNPs, of which 89 had concordant and 8 discordant effects on PAU and ANX. These loci mapped to 97 genes, including DRD2 and PDE4B , genes linked to dopaminergic and cAMP signaling pathways, respectively. Concordant gene expression was enriched in brain, nerve, adrenal gland, esophagus, stomach, and colon, with enriched expression specifically in the prefrontal cortex, anterior cingulate cortex, hippocampus, hypothalamus, substantia nigra and amygdala. FUMA cell-type enrichment analysis identified associations predominantly in neurons from the cerebral cortex, hippocampus, and thalamus. We found substantial genetic and neurobiological overlap between PAU and ANX, highlighting reciprocal, causal relationships between the traits, with differentially expressed genes enriched in addiction- and anxiety-relevant brain regions. These findings support shared genetic and neurobiological mechanisms linking PAU and ANX, while acknowledging that some signals may reflect broader internalizing or psychiatric liability.
- Open Access
- 3 July 2026
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 286, 113261
Assessing measurement bias in substance withdrawal symptoms attributable to childhood adversity and genetic liability
- 3 July 2026
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 286, 113261
Open AccessAssessing measurement bias in substance withdrawal symptoms attributable to childhood adversity and genetic liability
- Open Access
Suicidality phenotypes reflect both shared and distinct genetic factors
Suicidality phenotypes, including suicidal ideation (SI), non-fatal suicide attempt (SA), and suicide death (SD), are heritable and exhibit both shared and phenotype-specific genetic influences. Using genomic structural equation modelling, we estimated the shared genetic architecture across GWAS of SI (176,147 cases, 1,010,300 controls), SA (53,919 cases, 1,063,988 controls), and SD (7,584 cases, 652,070 controls) and conducted a multivariate GWAS of a latent suicidality factor capturing their shared liability. This analysis identified 36 genome-wide significant loci, including seven not previously reported in any suicidality GWAS. Follow-up analyses identified residual genetic variance specific to each phenotype, including three SD-specific genomic risk loci. Conditioning suicidality phenotypes on genetic liability to psychiatric disorders revealed significant residual genetic variance across SI, SA, SD, and the suicidality common factor. Together, these results suggest that suicidality reflects both shared genetic liability and phenotype-specific contributions.
Open AccessSuicidality phenotypes reflect both shared and distinct genetic factors
Suicidality phenotypes, including suicidal ideation (SI), non-fatal suicide attempt (SA), and suicide death (SD), are heritable and exhibit both shared and phenotype-specific genetic influences. Using genomic structural equation modelling, we estimated the shared genetic architecture across GWAS of SI (176,147 cases, 1,010,300 controls), SA (53,919 cases, 1,063,988 controls), and SD (7,584 cases, 652,070 controls) and conducted a multivariate GWAS of a latent suicidality factor capturing their shared liability. This analysis identified 36 genome-wide significant loci, including seven not previously reported in any suicidality GWAS. Follow-up analyses identified residual genetic variance specific to each phenotype, including three SD-specific genomic risk loci. Conditioning suicidality phenotypes on genetic liability to psychiatric disorders revealed significant residual genetic variance across SI, SA, SD, and the suicidality common factor. Together, these results suggest that suicidality reflects both shared genetic liability and phenotype-specific contributions.
- Open Access
- 18 May 2026
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 50 (5) , e70312
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
This narrative review evaluates glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as potential treatments for alcohol use disorder (AUD), a major public health problem with limited treatment options. We first briefly describe the development of GLP‐1RAs for treating type 2 diabetes and obesity and then focus on recent studies of the drugs' effects on alcohol‐related behaviors, both in animal models and clinical studies. We identified relevant literature by searching for studies of incretin‐based therapies using PubMed, Google Scholar, and clinicaltrials.gov and reviewing the reference lists of published reviews. We limited our discussion of preclinical studies of alcohol‐related effects to those that provide insights into the mechanism of effects. Clinical studies comprised both observational studies, including those using electronic health records and other real‐world data, and randomized controlled clinical trials, including studies completed or in progress. Of the clinical studies, we include original, peer‐reviewed research published in English and excluded case reports, commentaries, and preprints. This yielded a total of 13 preclinical studies, 14 clinical studies, 4 published interventional trials, and 19 interventional trials in progress or completed but unpublished. We found convergent evidence from animal and human studies that GLP‐1RAs reduce alcohol consumption and improve alcohol‐associated outcomes. Several randomized controlled trials (RCTs) in progress aim to test the effects of both established and novel compounds, and different drug formulations and combinations on alcohol consumption. Additional RCTs are needed to establish the efficacy of GLP‐1RAs for treating AUD, with mechanistic studies needed to elucidate more fully their mode of action in reducing alcohol consumption.
- 18 May 2026
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 50 (5) , e70312
Open AccessGLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
This narrative review evaluates glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as potential treatments for alcohol use disorder (AUD), a major public health problem with limited treatment options. We first briefly describe the development of GLP‐1RAs for treating type 2 diabetes and obesity and then focus on recent studies of the drugs' effects on alcohol‐related behaviors, both in animal models and clinical studies. We identified relevant literature by searching for studies of incretin‐based therapies using PubMed, Google Scholar, and clinicaltrials.gov and reviewing the reference lists of published reviews. We limited our discussion of preclinical studies of alcohol‐related effects to those that provide insights into the mechanism of effects. Clinical studies comprised both observational studies, including those using electronic health records and other real‐world data, and randomized controlled clinical trials, including studies completed or in progress. Of the clinical studies, we include original, peer‐reviewed research published in English and excluded case reports, commentaries, and preprints. This yielded a total of 13 preclinical studies, 14 clinical studies, 4 published interventional trials, and 19 interventional trials in progress or completed but unpublished. We found convergent evidence from animal and human studies that GLP‐1RAs reduce alcohol consumption and improve alcohol‐associated outcomes. Several randomized controlled trials (RCTs) in progress aim to test the effects of both established and novel compounds, and different drug formulations and combinations on alcohol consumption. Additional RCTs are needed to establish the efficacy of GLP‐1RAs for treating AUD, with mechanistic studies needed to elucidate more fully their mode of action in reducing alcohol consumption.
- 5 March 2026
- Published by American Psychological Association (APA) in Psychology of Addictive Behaviors
- Vol. 40 (5) , 503-512
Assessing measurement bias in substance use disorder criteria associated with childhood adversity and genetic liability.
The diagnosis and severity of substance use disorders (SUDs) are classified by the number of criteria endorsed. However, environmental and genetic factors may influence criterion endorsement. To evaluate this, we tested for differential item functioning of SUDs criteria by adverse childhood events (ACEs) and SUD polygenic scores. In 10,275 Yale-Penn participants (Mage = 40.59 years, 56.2% male, 47.21% of African-like genetic ancestry, 52.79% of European-like genetic ancestry), we used item response theory models to estimate difficulty and discrimination parameters for each criterion for alcohol, cannabis, and opioid use disorders. We then tested whether these properties varied based on scores on a latent ACEs factor and ancestry-specific polygenic scores using moderated nonlinear factor analyses. There was variability in the difficulty and discrimination of SUD criteria. Many criteria discriminated less effectively among individuals with higher ACEs factor scores. Continued substance use despite physical/psychological problems (β = .08, SE = 0.01, p < .0001) and withdrawal (β = .07, SE = 0.02, p = .001) were more difficult to endorse for individuals with high ACEs scores than those with lower ACEs scores. No differential item functioning was identified by polygenic scores. Findings highlight the impact of ACEs on SUD assessment. Considering the relative weighting of criteria or developing screening procedures that consider subgroup-specific differences in symptom functioning may help address these biases. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
- 5 March 2026
- Published by American Psychological Association (APA) in Psychology of Addictive Behaviors
- Vol. 40 (5) , 503-512
Assessing measurement bias in substance use disorder criteria associated with childhood adversity and genetic liability.
The diagnosis and severity of substance use disorders (SUDs) are classified by the number of criteria endorsed. However, environmental and genetic factors may influence criterion endorsement. To evaluate this, we tested for differential item functioning of SUDs criteria by adverse childhood events (ACEs) and SUD polygenic scores. In 10,275 Yale-Penn participants (Mage = 40.59 years, 56.2% male, 47.21% of African-like genetic ancestry, 52.79% of European-like genetic ancestry), we used item response theory models to estimate difficulty and discrimination parameters for each criterion for alcohol, cannabis, and opioid use disorders. We then tested whether these properties varied based on scores on a latent ACEs factor and ancestry-specific polygenic scores using moderated nonlinear factor analyses. There was variability in the difficulty and discrimination of SUD criteria. Many criteria discriminated less effectively among individuals with higher ACEs factor scores. Continued substance use despite physical/psychological problems (β = .08, SE = 0.01, p < .0001) and withdrawal (β = .07, SE = 0.02, p = .001) were more difficult to endorse for individuals with high ACEs scores than those with lower ACEs scores. No differential item functioning was identified by polygenic scores. Findings highlight the impact of ACEs on SUD assessment. Considering the relative weighting of criteria or developing screening procedures that consider subgroup-specific differences in symptom functioning may help address these biases. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
- Open Access
Pathways from Polygenic Risk to Suicidality: Effects of Alcohol Use Disorder and Childhood Adversity
Background: The prevalences of suicidal ideation (SI) and suicide attempt (SA) are influenced by genetic, behavioral, and environmental factors. Alcohol use disorder (AUD) and adverse childhood experiences (ACEs) may mediate or moderate genetic liability for suicidality. Methods: Using data from 10,275 participants (43.8% female; 47.2% African-like genetic ancestry [AFR], 52.8% European-like genetic ancestry [EUR]), we tested whether polygenic scores (PGS) for SI and SA predicted lifetime SI or SA. We also evaluated whether alcohol use disorder (AUD) mediated these associations and whether adverse childhood experiences (ACEs) moderated the direct and indirect pathways. Results: Although there were significant direct associations of the SA PGS with SA (AFR: b = 0.36, SE = 0.01; EUR: b = 0.17, SE = 0.01; both p s < 2e-16), the SI PGS did not predict SI (p > 0.55). AUD mediated SA genetic risk (average causal mediation effect (ACME): AFR = 0.01, 95% CI [0.01-0.01]; EUR = 0.02, 95% CI [0.01-0.02]; both p s < 2e-16). Moderation analyses indicated that indirect effects were attenuated by ACEs score (ΔACME: AFR = 0.02, p < 2e-16; EUR = 0.01, p = 0.03). There was neither mediation nor moderated mediation for SI. Conclusions: Genetic liability to SA operates partly through AUD, particularly among individuals with lower childhood adversity. Under higher adversity, alternative pathways to SA likely predominate. These findings highlight the need to consider distinct etiological pathways to the development of suicidality and the relevance of AUD as a modifiable target for suicide prevention among individuals at high genetic liability.
Open AccessPathways from Polygenic Risk to Suicidality: Effects of Alcohol Use Disorder and Childhood Adversity
Background: The prevalences of suicidal ideation (SI) and suicide attempt (SA) are influenced by genetic, behavioral, and environmental factors. Alcohol use disorder (AUD) and adverse childhood experiences (ACEs) may mediate or moderate genetic liability for suicidality. Methods: Using data from 10,275 participants (43.8% female; 47.2% African-like genetic ancestry [AFR], 52.8% European-like genetic ancestry [EUR]), we tested whether polygenic scores (PGS) for SI and SA predicted lifetime SI or SA. We also evaluated whether alcohol use disorder (AUD) mediated these associations and whether adverse childhood experiences (ACEs) moderated the direct and indirect pathways. Results: Although there were significant direct associations of the SA PGS with SA (AFR: b = 0.36, SE = 0.01; EUR: b = 0.17, SE = 0.01; both p s < 2e-16), the SI PGS did not predict SI (p > 0.55). AUD mediated SA genetic risk (average causal mediation effect (ACME): AFR = 0.01, 95% CI [0.01-0.01]; EUR = 0.02, 95% CI [0.01-0.02]; both p s < 2e-16). Moderation analyses indicated that indirect effects were attenuated by ACEs score (ΔACME: AFR = 0.02, p < 2e-16; EUR = 0.01, p = 0.03). There was neither mediation nor moderated mediation for SI. Conclusions: Genetic liability to SA operates partly through AUD, particularly among individuals with lower childhood adversity. Under higher adversity, alternative pathways to SA likely predominate. These findings highlight the need to consider distinct etiological pathways to the development of suicidality and the relevance of AUD as a modifiable target for suicide prevention among individuals at high genetic liability.
- Open Access
- 2 February 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e38
Education shares distinct genetic influences with substance use and disorder
Background: Educational attainment (EA), which comprises cognitive (CogEA) and noncognitive (NonCogEA) components, is positively genetically correlated with alcohol and cannabis use but negatively correlated with alcohol and cannabis use disorders (AUD and CUD). These paradoxical associations suggest that shared genetic influences with EA may differ by level of substance involvement. Methods: To test this, we examined the shared genetic architecture of EA, CogEA, and NonCogEA with alcohol consumption (AC), AUD, lifetime cannabis use (CanUse), and CUD. We used bivariate causal mixture models, local genetic correlation analyses, and conditional/conjunctional false discovery rate analyses to identify global, regional, and variant-level overlap for EA and substance-related trait pairs. Results: EA shared 57.57% of causal variants with AC and 62.42% with AUD, while sharing 48.07% of causal variants with CanUse and 84.18% with CUD. Among shared variants for AC, 48.12% had concordant effects with CogEA and 52.86% with NonCogEA. For AUD, 38.40% and 41.02% of causal variants had concordant effects with CogEA and NonCogEA, respectively. CanUse had higher concordance with CogEA (71.42%) and NonCogEA (65.56%) than CUD (37.97% and 42.23%, respectively). Functional enrichment in brain tissues varied across substance use and EA pairs. Conclusions: EA is associated with greater alcohol and cannabis use and lower risk for AUD and CUD, a pattern that reflects both concordant and discordant variant effects. CogEA and NonCogEA show partially distinct patterns, particularly for cannabis-related traits, highlighting the importance of disaggregating EA to clarify the genetic architecture underlying its paradoxical associations with substance-related traits.
- 2 February 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e38
Open AccessEducation shares distinct genetic influences with substance use and disorder
Background: Educational attainment (EA), which comprises cognitive (CogEA) and noncognitive (NonCogEA) components, is positively genetically correlated with alcohol and cannabis use but negatively correlated with alcohol and cannabis use disorders (AUD and CUD). These paradoxical associations suggest that shared genetic influences with EA may differ by level of substance involvement. Methods: To test this, we examined the shared genetic architecture of EA, CogEA, and NonCogEA with alcohol consumption (AC), AUD, lifetime cannabis use (CanUse), and CUD. We used bivariate causal mixture models, local genetic correlation analyses, and conditional/conjunctional false discovery rate analyses to identify global, regional, and variant-level overlap for EA and substance-related trait pairs. Results: EA shared 57.57% of causal variants with AC and 62.42% with AUD, while sharing 48.07% of causal variants with CanUse and 84.18% with CUD. Among shared variants for AC, 48.12% had concordant effects with CogEA and 52.86% with NonCogEA. For AUD, 38.40% and 41.02% of causal variants had concordant effects with CogEA and NonCogEA, respectively. CanUse had higher concordance with CogEA (71.42%) and NonCogEA (65.56%) than CUD (37.97% and 42.23%, respectively). Functional enrichment in brain tissues varied across substance use and EA pairs. Conclusions: EA is associated with greater alcohol and cannabis use and lower risk for AUD and CUD, a pattern that reflects both concordant and discordant variant effects. CogEA and NonCogEA show partially distinct patterns, particularly for cannabis-related traits, highlighting the importance of disaggregating EA to clarify the genetic architecture underlying its paradoxical associations with substance-related traits.